Generation Bio to Participate in 42nd Annual Cowen Health Care Conference
Generation Bio Co. (Nasdaq: GBIO) announced that its CEO, Geoff McDonough, will participate in the Gene Therapy panel at the 42nd Annual Cowen Health Care Conference on March 9 at 12:50 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Generation Bio Co. (Nasdaq: GBIO) announced that its CEO, Geoff McDonough, will participate in the Gene Therapy panel at the 42nd Annual Cowen Health Care Conference on March 9 at 12:50 p.m. ET. A live webcast will be available on the investor section of the company's website, with a replay accessible for 30 days following the event.
The company is focused on innovative genetic medicines aimed at providing durable treatments for rare and prevalent diseases, utilizing its proprietary non-viral genetic medicine platform.
Details
News Market Reaction – GBIO
The recorded move for GBIO in the trading session of this news was -2.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene Therapy panel discussion at the 42nd Annual Cowen Health Care Conference on Wednesday, March 9 at 12:50 p.m. ET.
A live webcast of the panel will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
For more information, please visit www.generationbio.com.
Contact:
Investors
Maren Killackey
Generation Bio
mkillackey@generationbio.com
541-646-2420
Media
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
617-903-8783
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.